10am-10:50am:  Justin Schweitzer, OD. FAAO

“The Glaucoma Balancing Act: Preserving the Ocular Surface and Optic Nerve Simultaneously” COPE # 81984-GL 1 hr.

Glaucoma is traditionally managed with topical application of pharmaceutical drops to lower IOP. Nearly 50% of patients require multiple topical medications to control their intraocular pressure which can lead to ocular surface disease, compliance issues, and a decline in quality of life ultimately all leading to progression of the disease. This course will explore alternative options to reduce the burden of topical glaucoma medications for your patients. This will include novel glaucoma drug delivery, the role of minimally invasive glaucoma surgery, and new formulations of topical glaucoma medications.

11am-11:50am:  Andrew Hammer, MD.

VISIONARY OPHTHALMOLOGY, ROCKVILLE, MD

“Update on New IOL Technologies for 2023” COPE # 83501-GO 1hr.

A complete overview of the newest technology in IOLs for post-cataract patients.

12pm-2pm: Jay Haynie, OD, FAAO, FORS

“Age Related Macular Degeneration and Masquerading Maculopathies”

COPE # 83169-TD   2 hrs.

Age Related macular Degeneration is the leading cause of legal blindness worldwide. The landscape for guidance on use of micronutrient supplements, treatment of neovascular AMD and the future of prospective options for our patients with non neovascular geographic AMD are evolving and we must stay up to date for our patients. This presentation will give you the most recent update on management of the patient with AMD. In addition, there are many macular diseases that may mimic AMD when it comes to symptoms and clinical findings. Differentiating masquerading maculopathies of AMD is crucial when discussing treatment and prognosis with your patient. Session fee: $88.00